International Clinics
Breaking
FDA approves Hibsago (bepirovirsen), a first-in-class treatment that may let some hepatitis B patients stop therapy
On 20 October 2026 the FDA approved GSK's Hibsago (bepirovirsen) injection for chronic hepatitis B.